Table 1. Main characteristics of HIV-infected women screened for cervical malignancies according to the presence or absence of cervical intraepithelial neoplasia of any grade (CIN+) in Abidjan, Côte d'Ivoire.
| No CIN+ | Presence of CIN+ | P | Total | |
| (n = 2,866) | (n = 132) | (n = 2,998) | ||
| HIV clinic, n (%) | 0.58 | |||
| MTCT + | 591 (20.6) | 32 (24.3) | 623 (20.8) | |
| Cepref | 1,303 (45.5) | 56 (42.4) | 1,359 (45.3) | |
| CNTS | 972 (33.9) | 44 (33.3) | 1,016 (33.9) | |
| Age in years, median (IQR) | 36 [32–42] | 37 [31–41] | 0.40 | 36 [32–42] |
| Formal education, n (%) | 0.67 | |||
| No | 725 (25.3) | 32 (24.3) | 757 (25.3) | |
| Primary school | 926 (32.3) | 39 (29.5) | 965 (32.2) | |
| Secondary and over | 1,213 (42.4) | 61 (46.2) | 1,274 (42.5) | |
| Tobacco use * | 43 (1.5) | 1 (0.8) | 0.49 | 44 (1.5) |
| Hormonal contraceptive use (current) | 45 (1.6) | 0 (0.0) | 0.26 | 45 (1.5) |
| Marital status | 0.02 | |||
| Married, cohabitant | 1,298 (45.3) | 46 (34.9) | 1,344 (44.8) | |
| Single, divorced, widowed | 1,568 (54.7) | 86 (65.1) | 1,654 (55.2) | |
| Age at first sexual intercourse, n (%) | 0.66 | |||
| ≥16 years | 1,949 (69.3) | 93 (71.0) | 1,946 (69.2) | |
| <16 years | 863 (30.7) | 38 (29.0) | 866 (30.8) | |
| Lifetime number of sexual partners | 0.21 | |||
| <5 | 1,247 (43.8) | 65 (49.2) | 1,312 (44.0) | |
| ≥5 | 1,602 (56.2) | 67 (50.8) | 1,669 (56.0) | |
| Parity, n (%) | 0.04 | |||
| Nulliparous | 448 (15.6) | 10 (7.6) | 458 (15.3) | |
| Primiparous | 687 (24.0) | 35 (26.5) | 722 (24.1) | |
| Multiparous | 1731 (60.4) | 87 (65.9) | 1818 (60.6) | |
| ART exposure (years) | 0.04 | |||
| Never on ART | 705 (24.9) | 26 (19.7) | 731 (24.6) | |
| ≥1 | 906 (32.0) | 54 (40.9) | 960 (32.4) | |
| ≥2–3 | 617 (21.8) | 33 (25.0) | 650 (21.9) | |
| ≥4 | 606 (21.3) | 19 (14.4) | 625 (21.1) | |
| If yes, current ART regimen | 2,161 (100.0) | 106 (100.0) | 0.44 | 2,267 (100.0) |
| D4T/3TC/NVP | 573 (26.5) | 23 (21.7) | 596 (26.3) | |
| D4T/3TC/EFV | 125 (5.8) | 7 (6.6) | 132 (5.8) | |
| AZT/3TC/NVP | 397 (18.3) | 23 (21.7) | 420 (18.5) | |
| AZT/3TC/EFV | 315 (14.6) | 13 (12.3) | 328 (14.5) | |
| Protease inhibitor based regimen | 207 (9.6) | 13 (12.3) | 220 (9.7) | |
| Other regimens | 544 (25.2) | 27 (25.4) | 571 (25.2) | |
| HIV type | 0.68 | |||
| HIV-1 | 1,694 (59.1) | 78 (59.1) | 1,772 (59.1) | |
| HIV-2 or dually reactive | 79 (2.8) | 2 (1.5) | 81 (2.7) | |
| Unknown | 1,093 (38.1) | 52 (39.4) | 1,145 (38.2) | |
| Baseline clinical stage | 0.94 | |||
| CDC A & B and/or 1,2 WHO | 1,513 (52.8) | 69 (52.3) | 1,582 (52.8) | |
| CDC C and/or 3,4 WHO | 962 (33.6) | 46 (34.8) | 1,008 (33.6) | |
| Unknown | 391 (13.6) | 17 (12.9) | 408 (13.6) | |
| Baseline CD4 count, median (IQR)† | 295 [160–464] | 249 [107–378] | <10−2 | 291 [156–461] |
| Most recent CD4 count, median (IQR)‡ | 458 [307–629] | 340 [216–500] | <10−4 | 452 [301–621] |
*Current or former use of smoked and/or chewed tobacco.
†
CD4 count (cells/mm3) measured during first clinical follow-up for HIV infection.
‡
Last known CD4 count (cells/mm3) measured prior or during the cervical cancer screening visit.
Abbreviations: CIN/ICC Cervical Intraepithelial Neoplasia/Invasive Cervical Cancer ART Antiretroviral Treatment.